Floatz logo

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)

Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)protein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
Cediranib
Fred Hutchinson Cancer Center
Phase 1/2CCC
Allopurinol
National Cancer Institute (NCI)
Phase 1/2CCC
ASPARAGINASE
National Cancer Institute (NCI)
Phase 1/2CCC
aciclovir
National Cancer Institute (NCI)
Phase 1/2CCC
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
CANDONI ANNA
Phase 1/2CCC

Same molecule, other indications

ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) is also rated in:

Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
L1 Childhood Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Untreated Childhood Acute Myeloid Leukemia and Other Myeloid MalignanciesDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →